Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
Clinical trial NCT03534323 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03534323
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-12
- Primary completion
- 2024-12-01
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.